Aims/hypothesis Endothelial cells are considered to be essential for normal pancreatic beta cell function. However, there have been no reports showing their importance for beta cell function. Materials and methods Using mice with disrupted vascular endothelial growth factor-A gene specifically in beta cells, we investigated the relation between islet vascular structure and beta cell function. Results Mice with disrupted vascular endothelial growth factor-A gene specifically in beta cells had reduced islet vascular density with impaired formation of endothelial fenestration. While their fasting glucose and body weight were comparable with control mice, their glucose-and tolbutamide-induced rapid insulin release were impaired, thus resulting in glucose intolerance. On the other hand, glucose and KCl enhanced the levels of insulin secreted from islets isolated from these mice. In addition, the production of soluble N-ethylmaleimide-sensitive factor attachment protein receptors in the islets was increased. Insulin content and expression of insulin I and pancreas duodenum homeobox 1 mRNA in the islets were also increased. Conclusions/interpretation Our results indicate that an abnormal quality and quantity of blood vessels due to reduced expression of vascular endothelial growth factor-A in beta cells could be a cause of impaired insulin secretion without impairment of beta cell function.
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Introduction
Insulin is secreted from pancreatic islets by various physiological secretagogues and an adequate and precise pattern of insulin secretion is essential to maintain normal blood glucose levels. To achieve normal dynamics of blood insulin levels, both the beta cells and vascular system in islets may play important roles [1] . The islet capillary network is about five times denser than that of the exocrine tissue and the microvasculature of pancreatic islets consists of thin fenestrated endothelial cells separated from beta cells by the basement membrane [1, 2] . The islet microvasculature has a unique relationship with beta cells, which are polarised with one domain facing an arterial capillary and another facing a venous capillary [3] . In addition, islets contain canaliculi located between the lateral faces of beta cells. These canaliculi contain many microvilli with high production of GLUT2 (now known as solute carrier family 2 [facilitated glucose transporter], member 2) [4] . These vascular networks might contribute to the rapid sensing of blood glucose in beta cells and the rapid trans-endothelial passage of insulin follows highly regulated exocytosis of insulin-containing granules. However, both the role of the islet vascular system as such in physiological glucose tolerance in vivo, and its impact remain elusive. In the pancreas, vascular endothelial growth factor (VEGF)-A is highly produced in islets compared with exocrine cells [5, 6] . VEGF is a key regulator of vasculogenesis, angiogenesis, vascular permeability, and endothelial fenestration formation [7] [8] [9] . As demonstrated previously, beta cell-specific deletion of Vegfa (seen in mice in which cyclisation recombination [CRE] [6] . In addition, pancreatic-specific deletion of Vegfa (seen in mice in which CRE recombinase is under transcriptional control of the pancreas duodenum homeobox1 [PDX1; PDX1-CRE], in combination with a VEGF fl/fl ; PDX1-CRE: VEGF fl/fl ) also results in reduced vascularisation and fenestration of islet capillaries [10] . Although other family members of VEGF are expressed in beta cells [6] , these results clearly indicate that VEGFA in the pancreas plays a nonredundant role in the formation of dense fenestrated capillaries in islets.
VEGFA binds to VEGF receptor (VEGFR)-1 (also known as FMS-like tyrosine kinase 1 [FLT1]) and VEGFR-2 (also know as kinase insert domain protein receptor [KDR]), the production of which is largely restricted to endothelial cells. On the other hand, other family members also bind to VEGFR-1 and VEGFR-2. Thus placental growth factor and VEGFB can bind to VEGFR-1, while VEGFC and VEGFD can bind to VEGFR-2 [11] . A recent study investigated the effect of AG-013736, which inhibits VEGF receptor tyrosine kinases, including VEGFR-1, VEGFR-2, soluble VEGFR-1 (which inhibits the ligand binding to VEGFR-1) and soluble VEGFR-2 (which inhibits the ligand binding to VEGFR-2), on microvasulature in several tissues [5] . The investigators demonstrated that administration of AG-013736 results in a 60% decrease in intra-islet microvasculature, that soluble VEGFR-1 results in a 54% decrease in intra-islet microvasculature, and that soluble VEGFR-2 results in a 14% decrease in intra-islet vasculature. These findings suggest that VEGFA plays an important role in intra-islet vascular structure through binding to VEGFR-1, although other factors could partly substitute the effect of VEGFA.
PDX1-CRE:VEGF fl/fl mice show glucose intolerance with a reduced number of insulin-containing granules in their islets [10, 12] . However, it is not clear whether the impaired glucose tolerance in this model is caused by a defect in beta cells or in the vascular system. In addition, pancreatic organogenesis is highly regulated by blood vessels as a source of developmental signals [13] . While the apparent morphological defect has not been reported in this model, the effect of Vegfa deletion in the early developmental stage might be important. Thus, in this study, we used mice with beta-cell-specific deletion of Vegfa to elucidate the functional role of the islet microvascular system.
Materials and methods

Animals
The study protocol was reviewed and approved by the Animal Care and Use Committee of Juntendo University, School of Medicine and Osaka Medical Center for Cancer and Cardiovascular Disease (both Japan). All mice were housed in specific pathogen-free barrier facilities, with a 12-h light-dark cycle, and free access to standard rodent food (Oriental Yeast, Osaka, Japan) and water.
In this study, the bacteriophage CRE/loxP-specific recombination system was used to generate a beta-cellspecific Vegfa-null allele. The generation and characterisation of RIP-CRE transgenic mice [14] , and VEGF mice to obtain RIP-CRE:VEGF fl/fl mice in the next generation. In parallel, we mated RIP-CRE mice with wild-type C57BL/6J to obtain RIP-CRE mice in the next generation. All mice used in this study were backcrossed to C57BL/6J for a minimum of nine generations prior to the initiation of the crosses to generate the compound transgenic/knock-out mice. Genomic PCR analysis for determination of genotype was performed as described previously [6] .
Immunohistochemical analysis After anaesthetisation of 20-week-old mice, the pancreas was removed after heart perfusion, and fixed in a solution of 4% paraformaldehyde or zinc formalin at 4°C overnight. The fixed tissue was embedded in paraffin and mounted on slides. Immunohistochemical analysis was carried out using antibodies for insulin (Linco Research, St Charles, MO, USA; dilution 1:200), glucagon (Linco; dilution 1:200) and CD31 (Pharmingen, San Diego, CA, USA; dilution 1:200) as described previously [16] . The percentage of area immunopositive for CD31 and glucagon, as well as islet beta cell area were determined on CD31-, glucagon-, and insulin-stained sections captured with a microscope (E800; Nikon, Tokyo, Japan) connected to an XYZ controller and digital camera (Sony, Tokyo, Japan). Each area was determined on ten immunostained sections from five mice each, with each section separated by at least 200 μm. The areas of positive staining were automatically measured using an image analysis software (Image Pro4.5J; Planetron, Tokyo, Japan). Non-specific staining was excluded from the quantification. The percentage areas immunopositive for CD31 and glucagon represented the respective immunopositive area relative to the whole islet area. The percentage of beta cell area was calculated by the following formula: islet beta cell area (%) = the area stained by insulin antibody/the area of the whole pancreatic area.
Electron microscopy Each mouse (20-week-old) was anaesthetised with pentobarbital sodium and the pancreas was removed after heart perfusion and fixed in a solution of 2.5% glutaraldehyde. The pancreas was cut into pieces of approximately 1 mm 3 . When using the isolated islets as samples, the islets were fixed in a solution of 2.5% glutaraldehyde soon after isolation. The samples were fixed for 2 h in 2.5% glutaraldehyde buffered to pH 7.4 with phosphate buffer, and treated with osmium tetroxide for 2 h at 4°C. The tissues were dehydrated with graded concentration ethanol, and then embedded in Epon 812 (TAAB Laboratories, Reading, Berks, UK). Thin sections were cut with a Leica Ultracut UCT (Leica Microsystems, Tokyo, Japan) with a diamond knife and stained with uranyl acetate followed by lead citrate [17] . Electron micrographs were taken with a JEOL JEM-1200EX electron microscope (JEOL, Tokyo, Japan) operated at 80 kV. Using images of electron micrographs, we measured the area of insulincontaining granules in three single beta cells from five mice in each group using an image analysis software (Image Pro4.5J).
Measurement of blood glucose and insulin concentrations in vivo For details on methods, see Electronic supplementary material (ESM).
Assay of insulin secretion from isolated islets and islet insulin content Pancreatic islets were isolated from 12-week-old mice by collagenase digestion as described previously [18] . The islets were pre-incubated for 30 min in Krebs-Ringer solution (KRS) at 37°C with 5% CO 2 and saturated humidity. Size-matched islets (n=10) were incubated in 400 μl KRS containing various insulinotrophic agents for 30 min at 37°C. At the end of incubation, aliquots of the buffer were immediately sampled and all samples were kept at −80°C until assay. For measurement of islet insulin content, islets were solubilised in acidethanol solution overnight at 4°C. Insulin concentration was analysed by RIA kit (Linco). Islet insulin concentration was corrected by DNA contents.
Islet perifusion The kinetics of insulin release was studied in vitro using a perifusion system. Pancreatic islets were isolated as mentioned above and used freshly after isolation. Size-matched islets (n=50) were placed in each column. Then the columns were gently closed with the top adaptors, immersed in a vertical position in a temperaturecontrolled water bath at 37°C. The perifusion medium was maintained at 37°C in a water-bath. All columns were perifused in parallel at a flow rate of 0.5 ml/min with KRS (2.8 mmol/l glucose) and at 37°C. After 60 min of static incubation with KRS (2.8 mmol/l glucose), the islets were stimulated by the continuous presence of 16.7 mmol/l glucose. Samples were collected every 20 s until 2 min, every 1 min until 5 min, and thereafter every 5 min until 30 min [19] . Samples were immediately stored at −80°C until further analysis. Insulin concentration was measured with an insulin RIA kit (Linco).
Tissue RNA isolation and real-time quantitative RT-PCR Total RNA was isolated from approximately 200 islets using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and first-strand cDNA was synthesised using 3 μg of total RNA with OligodT primers and superscript reverse transcriptase (Invitrogen). For the quantitative SYBR Green real-time PCR, cDNA was analysed with a PCR instrument (ABI 7700; Applied Biosystems, Foster City, CA, USA) and 2× SYBR Green PCR Master Mix (Applied Biosystems) and specific primers. Thermal cycles for amplification were set as follows: 2 min at 50°C, 10 min at 95°C and 40 cycles of 95°C for 45 s, 60°C for 45 s, and 72°C for 45 s. By this protocol, neither non-specific primer-dimer amplification, nor PCR products were observed in no-template control samples. Single band PCR products were detected by 1% agarose gels with end-reaction products. The relative expression levels of mRNAs were calculated by the cycle threshold method with standard cDNA. We used β-actin mRNA as the internal invariant standard. The primers used in this study are listed in ESM Table 1 .
Statistical analysis Results are expressed as mean±SEM. The unpaired Student's t test was used to compare the laboratory data of two groups. When comparisons of more than three groups were required, statistical significance was determined by one-way ANOVA and Scheffé's method as a post hoc test. p<0.05 was considered significant.
Results
Morphology of islets in RIP-CRE:VEGF
fl/fl mice Recently, Lee et al. [20] reported that RIP-CRE mice showed glucose intolerance with impaired insulin secretion. Thus, we used both RIP-CRE mice and VEGF fl/fl mice as controls in this study. As we described previously [6] , RIP-CRE:VEGF fl/fl mice showed a remarkable reduction of immunoreactivity of VEGFA in islets. Quantification of the area positive for CD31 revealed a marked reduction of islet endothelial cells in RIP-CRE:VEGF fl/fl mice compared with RIP-CRE and VEGF fl/fl mice (Fig. 1) . To further investigate the structural change in endothelial cells in islets of RIP-CRE:VEGF fl/fl mice, we examined endothelial morphology of islets by means of electron microscopy. Thin fenestrated endothelial cells were observed in the control VEGF fl/fl (CRE − ) mice (Fig. 2a,c,e) and RIP-CRE mice (data not shown). On the other hand, extensive changes were observed in endothelial cells in islets from RIP-CRE:VEGF fl/fl mice, these changes being characterised by little fenestration and increased caveolae-like structures (Fig. 2b,d,f) . In addition, the (Fig. 2g) . The amount and distribution of alpha cells in islets was not altered in RIP-CRE:VEGF fl/fl mice ( Fig. 3a-d) . Quantitative morphometry showed that the islet beta cell mass in RIP-CRE:VEGF fl/fl pancreas was comparable with that in RIP-CRE and VEGF fl/fl (CRE − ) pancreas ( Fig. 3e-h ). Thus, apart from the abnormality of islet endothelial cells, we did not find any obvious morphological abnormality in islets of RIP-CRE:VEGF fl/fl mice. mice was comparable with that of RIP-CRE mice and VEGF fl/fl mice (data not shown). While fasting glucose levels were comparable among the groups (Fig. 4a,b) , an intraperitoneal glucose challenge test identified glucose intolerance with impaired glucose-stimulated insulin secretion in RIP-CRE:VEGF fl/fl mice ( Fig. 4a-d) . Glucose intolerance was persistently observed from 8 to 20 weeks of age (Fig. 4a,b , and data not shown). A slight deterioration of glucose tolerance was observed with ageing, although no apparent decrease in insulin secretion was noted. It is probable that the ageing-related worsening of glucose tolerance was due to an ageing-related increase in insulin resistance. In addition, glucose tolerance and glucose-stimulated insulin secretion were also comparable in RIP-CRE and VEGF fl/fl mice. Thus, our results indicate that not the expression of Cre, but the deletion of Vegfa in beta cells impairs the rapid insulin release induced by increased glucose levels in the RIP-CRE:VEGF fl/fl mice. RIP-CRE:VEGF fl/fl mice also showed a decrease in tolbutamide-stimulated insulin secretion and arginine-stimulated glucagon secretion (Fig. 4e-h ). These results suggest that deletion of Vegfa in beta cells results in impaired hormone release from islets.
Increased insulin secretion in isolated islets in RIP-CRE: VEGF
fl/fl mice To elucidate whether the impaired insulin secretion observed in RIP-CRE:VEGF fl/fl mice was caused by impaired beta cell function, we investigated glucosestimulated insulin secretion using isolated islets. First, we compared ultrastructural changes in isolated VEGF fl/fl ) and RIP-CRE:VEGF fl/fl islets. As observed in pancreatic sections, the increase in insulin-containing granules in RIP-CRE:VEGF fl/fl beta cells remained higher than in control mice (ESM Fig. 1 ). According to a previous study [21] , most endothelial cells remain in islets in the period soon after the isolation procedures. However, very few residual endothelial cells and several openings in the intercellular space were observed in both VEGF fl/fl (CRE − ) and RIP-CRE:VEGF fl/fl islets (ESM Fig. 1 ). Because insulin secretagogues can directly infiltrate beta cells, at least in this condition, it is possible to investigate islet function after eliminating the major influence of endothelial cell dysfunction. In contrast to beta cell function in RIP-CRE:VEGF fl/fl mice in vivo, glucose-and KCl-stimulated levels of secreted insulin from isolated islets of RIP-CRE:VEGF fl/fl mice were not lower, but instead higher than from RIP-CRE and VEGF fl/fl (CRE − ) islets (Fig. 5a) . Islet perifusion studies also revealed that the rapid insulin secretion of RIP-CRE:VEGF fl/fl islets was higher than RIP-CRE, and VEGF fl/fl (CRE − ) mice (Fig. 5b) . To further investigate the mechanism of increased insulin secretion in RIP-CRE:VEGF fl/fl islets, we quantitated insulin content and mRNA of RIP-CRE:VEGF fl/fl islets. Insulin content and insulin I (Ins1) mRNA in RIP-CRE: VEGF fl/fl islets was higher than in control islets (Fig. 6 ). Previous data have demonstrated that several transcription factors orchestrate the expression of insulin gene [22] . Of these, PDX1 is one of the most important. Thus, we quantitated the expression level of Pdx1 mRNA in RIP-CRE, and VEGF fl/fl (CRE − ) mice. We found that RIP-CRE: VEGF fl/fl islets express higher levels of Pdx1 mRNA than control islets. In addition, because RIP-CRE:VEGF fl/fl islets contain more insulin-containing granules and secrete more insulin than control mice in vitro, we investigated whether the morphological increase in insulin granules accompanies the increase in essential components of exocytosis. Soluble N-ethylmaleimide-sensitive factor attachment protein receptors (SNARE) and its related proteins are among these components. As shown in express higher levels of the genes encoding SNARE and its related proteins. Thus, it is likely that the increase in insulin secretion in RIP-CRE:VEGF fl/fl islets is simply due to an increase in the releasable pool of insulin granules that comes with an increase in Ins1 mRNA.
Discussion
In this study, we investigated the role of VEGFA on beta cell function using RIP-CRE:VEGF fl/fl mice, in which Vegfa has been disrupted specifically in beta cells. Our major findings are that RIP-CRE:VEGF fl/fl mice exhibited impaired glucose tolerance with reduced rapid insulin release, whereas isolated islets of RIP-CRE:VEGF fl/fl have greater insulin content and show higher insulin secretion. Thus, the impaired formation of endothelial cells in islets is involved in the impaired glucose-stimulated insulin secretion.
Previous reports have indicated that VEGFA plays an essential role in the maintenance of endothelial cell number and formation of endothelial fenestration [8, 23] . PDX1-CRE:VEGF fl/fl mice [10] have few endothelial cells, reduced fenestrate and increased caveolae in residual islet endothelial cells. As shown in the present study, RIP-CRE: VEGF fl/fl mice showed similar morphological changes in islet endothelial cells. The main difference, however, was that the islets of these mice showed an increased number of insulin-containing granules, although it has been reported that PDX1-CRE:VEGF fl/fl mice had a reduced number of insulin-containing granules in the islets [10] . PDX1 production occurs before formation of the pancreatic bud in pancreatic primordial tissue [24, 25] . Theoretically, VEGFA is deleted in whole pancreatic epithelial-derived cells early in the development of the pancreas in PDX1-CRE:VEGF fl/fl mice. In contrast, in RIP-CRE:VEGF fl/fl mice, VEGFA is deleted only in insulin-producing cells and the recombination event commences at a later stage of pancreatic development. Thus, we cannot rule out the possibility that the difference in phenotype might be based on the difference of timing and cells of the recombination event. Alternatively, this difference could result from the number of residual functional endothelial cells. Based on recent data, beta cells, in contrast to exocrine pancreatic cells, do not form a basement membrane [12] . Instead, endothelial cells form vascular basement membrane next to the beta cells in islets. Laminins, a vascular basement membrane protein, promote insulin gene expression and proliferation of beta cells [12] . Taking these findings into account, the residual amounts of endothelial cells seem to affect insulin contents. In fact, the relative reduction of endothelial cell area in the islets of PDX1-CRE:VEGF fl/fl mice was reported to be 84%. On the other hand, the relative reduction of endothelial cell area in the islets of RIP-CRE:VEGF fl/fl mice was 60.5% (Fig. 1) . If the threshold for the number of functional endothelial cells that results in reduced insulin content lies between that in PDX1-CRE:VEGF fl/fl mice and that in RIP-CRE:VEGF fl/fl mice, the difference in insulin content between these mice might be due to the number of residual endothelial cells. If so, the association between the number of endothelial cells and insulin content should not be linear. Clearly, further assessment is needed to complete our understanding of the impact of VEGFA in islets on insulin contents. In RIP-CRE:VEGF fl/fl mice, we found increases in the following: (1) expression of Pdx1, a transcription factor of insulin gene; (2) expression of Ins1 mRNA; (3) insulin content in islets; (4) insulin granules in beta cells; and (5) the expression of genes encoding molecules implicated in regulated exocytosis, such as mammalian homologue of the unc-18, vesicular-associated membrane protein 2, synaptosomal-associated protein of 25 kDa, and syntaxin-1A. These changes could be a cause of the hypersecretion of insulin observed in vitro and seemed to be a compensatory response for the decreased insulin secretion in vivo. However, according to recent work [5] , both the decoy VEGF ligand and the small molecule VEGF receptor tyrosine kinase blocker can ameliorate glucose tolerance with decreased fasting glucose levels, without improving insulin sensitivity judged by an insulin tolerance test. In that study, no further information on the mechanism was provided. One possibility is that administration of the decoy VEGF ligand and the small molecule VEGF receptor tyrosine kinase blocker impaired the function of adrenal cortex or pituitary gland, which secrete counter-regulatory hormones through the decreased microvasculature structure. In fact, the authors [5] found increased serum thyroid stimulating hormone levels with decreased thyroid microvasculature as a result of treatment with VEGFA blockade. Thus, it is possible that the function of other endocrine organs might be impaired.
On the other hand, we cannot deny the possibility that VEGFA in beta cells somehow deteriorates beta cell function through an unknown mechanism. If so, the increased insulin content and insulin secretion observed in isolated islets of RIP-CRE:VEGF fl/fl mice was reasonable. In this case, in vivo phenotypical differences between RIP-CRE:VEGF fl/fl mice and the administration of VEGFA inhibition might depend on the timing and periods of VEGFA blockade.
Apart from the direct effect via disturbed VEGFA signalling, recent data suggest that an autocrine effect of insulin through insulin receptor/phosphatidylinositol-3 kinase signalling pathways mediates beta cell function [26] [27] [28] [29] [30] . In RIP-CRE:VEGF fl/fl mice, trans-endothelial passage of insulin might be impaired, possibly making the concentration of insulin around beta cells higher than in control mice. If so, in RIP-CRE:VEGF fl/fl mice, the insulin signal should be enhanced. This might be one of the reasons for the higher insulin content in RIP-CRE:VEGF fl/fl mice. Thus, from the above-mentioned possibilities, the increased insulin content and improved function of RIP-CRE:VEGF fl/fl in vitro might not merely reflect a compensatory phenomenon in beta cells for impaired islet vascular function and impaired glucose tolerance in vivo.
The islet microvasculature network is thought to be important for both the quick sensing of blood glucose in beta cells and the rapid trans-endothelial passage of insulin. In the present study, insulin secretion stimulated by glucose and tolbutamide in RIP-CRE:VEGF fl/fl mice was decreased. In addition, arginine-stimulated glucagon secretion was also decreased. Thus, although it is difficult to elucidate whether glucose sensing is impaired in RIP-CRE:VEGF fl/fl mice, our data suggest that at least the permeability of substances from the blood stream and/or rapid trans-endothelial passage of hormones in islets was disturbed, and that this abnormality is involved in the abnormality of hormone secretion in these mice.
Recently, Lee et al. [20] reported that RIP-CRE mice suffer from impaired pancreatic beta cell function. In contrast to their report, our data revealed that glucose tolerance in RIP-CRE mice is comparable with that of VEGF fl/fl mice. In addition, we found no differences regarding insulin secretion between RIP-CRE mice and VEGF fl/fl mice. We do not know the exact reason for this discrepancy in this study. Because we set RIP-CRE mice as a control in most parts of the experiments, the phenotype observed in RIP-CRE:VEGF fl/fl mice is not due to some toxic effect of the expression of Cre in beta cells.
RIP-CRE mice are known to show leaky production of CRE recombinase in the hypothalamus. Thus, we should take into account the effect of VEGFA in hypothalamus on the phenotype of RIP-CRE:VEGF fl/fl mice. According to recent findings [5] , the administration of VEGFA blockers decreased endothelial cells in islets, thyroid, small intestine villi, adrenal cortex, and choroid plexus, etc. On the other hand, the inhibition of VEGFA resulted in almost no effect on the microvasular structure in brain cortex and adrenal medulla. These findings suggest that the neural tissues contain very few VEGFA-dependent endothelial cells. Thus, VEGF deletion in hypothalamus rarely affects glucose tolerance.
Our data clearly suggest that disorganisation of islet vascularisation can impair glucose-stimulated insulin release, even if the function of beta cells is not impaired. We provide here evidence for the disorganisation of islet microcirculation as a mechanism of impaired insulin secretion. While adequate revascularisation is crucial for islet survival after transplantation, the vascular density in revascularised transplanted islets is markedly decreased [31] . In addition, previous data have demonstrated that the first phase of glucose-stimulated insulin release from islets transplanted to the liver was delayed, and less prominent when compared to that from the pancreas [32] . Considering islet function after transplantation, the decrease in islet vascular structure might be a main cause of decreased beta cell function. Our data clearly suggest that improved islet microvasculature could be a clue not only to islet survival, but also to maintaining normal islet function. In addition, our data suggest that the factors affecting islet endothelial cell formation could be a cause of the impaired glucosestimulated insulin secretion that is a typical feature of patients with type 2 diabetes.
